Anzeige
Mehr »
Sonntag, 22.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
194 Leser
Artikel bewerten:
(0)

LeadsRx Commits to IAB Europe's Transparency and Consent Framework

PORTLAND, OR / ACCESSWIRE / October 27, 2020 / LeadsRx, a marketing attribution company, continues its commitment to consumer trust and privacy by advancing transparency in marketing attribution by adopting IAB Europe's Transparency and Consent Framework (The Framework).

Consumer consent is a critical foundation to the evolution of advertising technology, and marketers should strive to understand all the ways consumers connect with and trust their brands.

"Transparency is a fundamental requirement for impartial marketing attribution success because it builds consumer trust in the analytics process," said AJ Brown, CEO and co-founder of LeadsRx. "LeadsRx is proud to be the first attribution vendor to commit to IAB's The Framework, and I'm confident other attribution technologies, ad-tech vendors, and marketing analytics providers will follow-suit."

Building Consumer Trust with Enterprise Attribution = Consumer Consent

Marketing attribution, which maps the consumer journey, provides the most useful insights when working with declarative consumer preferences in advertising as opposed to trying to second-guess what consumers want and don't want to engage with.

This means consumers must be given the option to opt-in or opt out. Allowing consumers to have control of their personally identifiable information (PII) gives them the option of choosing to share information with brands they decide to do business with and to share a level of trust to maintain a relationship with a brand.

By being a trusted third party, registered and approved by IAB, LeadsRx is the first marketing attribution provider to voluntarily adopt The Framework. LeadsRx continues its unwavering commitment to impartial and accurate attribution data.

"LeadsRx was an early adopter of consumer privacy and consent with a policy of only collecting anonymous data through its marketing attribution platform," said Brown. "Even IP addresses can be anonymized to prevent identification of households or individuals, and the only first-data captured by the LeadsRx Universal Conversion Tracking Pixel is declared by the individual.

"Adopting The Framework ensures LeadsRx has the people, processes and practices in place all along the digital advertising chain to meet the data security and privacy requirements people expect today."

For more information about LeadsRx and its commitment to privacy and building trust with consumers please visit LeadsRx.com. For details on IAB Europe's Transparency and Consent Framework visit https://iabtechlab.com/standards/gdpr-transparency-and-consent-framework/.

About LeadsRx

A fast innovator and a marketer's choice for 4,000-plus global and local brands, LeadsRx is an unrivalled multi-touch attribution SaaS platform. Powered by a unique Universal Conversion Tracking Pixel, LeadsRx provides an impartial view of customer journeys, giving each advertising touchpoint proper weight and credit including broadcast media. Founded by marketers, LeadsRx enables companies of any size to elevate marketing performance in a framework that is easily understood delivering sustainable return on ad spend (ROAS). To learn more about how LeadsRx can support you in marketing transformation visit LeadsRx.com. Connect with LeadsRx on Twitter, LinkedIn and Facebook.

For more information

Jeff Fishburn
Fishburn PR for LeadsRx
jeff@fishburnpr.com

SOURCE: LeadsRx



View source version on accesswire.com:
https://www.accesswire.com/610738/LeadsRx-Commits-to-IAB-Europes-Transparency-and-Consent-Framework

© 2020 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.